Treatment of latent tuberculosis infection with short‐course regimens in potential living kidney donors

2020 ◽  
Vol 22 (2) ◽  
Author(s):  
Jacques Simkins ◽  
Christian Donato‐Santana ◽  
Michele Ileana Morris ◽  
Lilian Margarita Abbo ◽  
Jose Fernando Camargo ◽  
...  
Keyword(s):  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Kidney Donors ◽  
Living Kidney Donors ◽  
Short Course

scholarly journals Safety of the Rifampin and Pyrazinamide Short-Course Regimen for Treating Latent Tuberculosis Infection

2007 ◽  
Vol 44 (3) ◽  
pp. 464-465 ◽  
Author(s):  
K. Ijaz ◽  
P. D. McElroy ◽  
J. Jereb ◽  
T. R. Navin ◽  
K. G. Castro
Keyword(s):  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Short Course

scholarly journals Safety and Completion Rate of Short‐Course Therapy for Treatment of Latent Tuberculosis Infection

2006 ◽  
Vol 43 (3) ◽  
pp. 271-275 ◽  
Author(s):  
Paul P. Cook ◽  
Ricardo A. Maldonado ◽  
Connie T. Yarnell ◽  
Don Holbert
Keyword(s):  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Completion Rate ◽  
Tuberculosis Infection ◽  
Short Course

scholarly journals Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection

2019 ◽  
Author(s):  
Amit Kaushik ◽  
Nicole C. Ammerman ◽  
Sandeep Tyagi ◽  
Vikram Saini ◽  
Iwan Vervoort ◽  
...  
Keyword(s):  
Mouse Model ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Positive Control ◽  
Negative Control ◽  
Tuberculosis Infection ◽  
Sustained Activity ◽  
Short Course ◽  
Long Acting ◽  
Aerosol Infection

ABSTRACTThe potent anti-tuberculosis activity and long half-life of bedaquiline make it an attractive candidate for long-acting/extended release formulations for treatment of latent tuberculosis infection (LTBI). Our objective was to evaluate a long-acting injectable (LAI) bedaquiline formulation in a validated paucibacillary mouse model of LTBI. Following immunization with Mycobacterium bovis rBCG30, BALB/c mice were challenged by aerosol infection with M. tuberculosis H37Rv. Treatment began 13 weeks after challenge infection with one of the following regimens: untreated negative control; positive controls of daily rifampin (10 mg/kg), once-weekly rifapentine (15 mg/kg) and isoniazid (50 mg/kg), or daily bedaquiline (25 mg/kg); test regimens of one, two, or three monthly doses of LAI bedaquiline at 160 mg/dose (BLAI-160); and test regimens of daily bedaquiline at 2.67 (B2.67), 5.33 (B5.33), or 8 (B8) mg/kg to deliver the same total bedaquiline as one, two, or three doses of BLAI-160, respectively. All drugs were administered orally, except for BLAI-160 (intramuscular injection). The primary outcome was the decline in M. tuberculosis lung CFU counts during 12 weeks of treatment. The negative and positive control regimens performed as expected. One, two, and three doses of BLA-160 resulted in decreases of 2.9, 3.2, and 3.5 log10 CFU/lung, respectively by week 12. Daily oral dosing with B2.67, B5.33, and B8 decreased lung CFU counts by 1.6, 2.8, and 4.1 log10, respectively. One dose of BLAI-160 exhibited activity for at least 12 weeks. The sustained activity of BLAI-160 indicates promise as a short-course LTBI treatment requiring few patient encounters to ensure treatment completion.

scholarly journals Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study

2018 ◽  
Vol 52 (6) ◽  
pp. 1801470 ◽  
Author(s):  
Lei Gao ◽  
Haoran Zhang ◽  
Henan Xin ◽  
Jianmin Liu ◽  
Shouguo Pan ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
World Health ◽  
Controlled Study ◽  
Short Course ◽  
Significant Difference ◽  
Randomised Controlled ◽  
Active Disease

Latent tuberculosis infection (LTBI) management is now a critical component of the World Health Organization's End TB Strategy.In this randomised controlled trial (Chinese Clinical Trial Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50–69 years with LTBI in China.Due to the increasingly rapid growth and unexpected high frequency of adverse effects, the treatments were terminated early (after 8 weeks for the once-weekly regimen and after 6 weeks for the twice-weekly regimen). In the modified intention-to-treat analysis on the completed doses, the cumulative rate of active disease during 2 years of follow-up was 1.21% (14 out of 1155) in the untreated controls, 0.78% (10 out of 1284) in the group that received the 8-week once-weekly regimen and 0.46% (six out of 1299) in the group that received the 6-week twice-weekly regimen. The risk of active disease was decreased, with an adjusted hazard ratio of 0.63 (95% CI 0.27–1.43) and 0.41 (95% CI 0.15–1.09) for the treatments, respectively. No significant difference was found in the occurrence of hepatotoxicity (1.02% (13 out of 1279) versus 1.17% (15 out of 1279); p=0.704).The short regimens tested must be used with caution among the elderly because of the high rates of adverse effects. Further work is necessary to test the ultrashort regimens in younger people with LTBI.

Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

2002 ◽  
Vol 137 (8) ◽  
pp. 640 ◽  
Author(s):  
Robert M. Jasmer ◽  
Jussi J. Saukkonen ◽  
Henry M. Blumberg ◽  
Charles L. Daley ◽  
John Bernardo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Multicenter Clinical Trial ◽  
Short Course

scholarly journals High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection—A single center study

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0253159
Author(s):  
Heng Yang ◽  
Yang Yang ◽  
Zhi-dong Hu ◽  
Lu Xia ◽  
Xu-hui Liu ◽  
...  
Keyword(s):  
Latent Tuberculosis Infection ◽  
Gastrointestinal Symptoms ◽  
Latent Tuberculosis ◽  
Completion Rate ◽  
Tuberculosis Infection ◽  
High Rate ◽  
Controlled Clinical Trial ◽  
Short Course ◽  
Clinical Center ◽  
Lost To Follow Up

Three months of weekly rifapentine plus isoniazid (3HP) is a short course regimen for latent tuberculosis infection treatment with satisfied safety and efficacy. However, research on its use in children is limited. In this study, we evaluated the completion rate and safety of the 3HP regimen among children in China. Participants aged 1–14 years receiving 3HP for TB prevention at Shanghai Public Health Clinical Center were followed from December 2019 to November 2020 to evaluate the safety and completion rate of the treatment. Thirty-one children were eligible for inclusion, but five were excluded from the analysis (three were treated with a lower than recommended dose, and two were lost to follow-up). Of the 26 children included in the analysis, the treatment completion rate was 100%. Adverse drug reactions (ADRs) were reported in 38.5% (10/26) of the patients. The most common ADRs were gastrointestinal symptoms (19.2%,5/26), and all ADRs were rated as Grade 1. The 3HP regimen has a high completion rate, and it seems well tolerated in our study population. However, further randomized controlled clinical trial with larger sample size are warranted.

Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV Infection

CHEST Journal ◽  
2002 ◽  
Vol 122 (4) ◽  
pp. 1292-1298 ◽  
Author(s):  
Masahiro Narita ◽  
Michael Kellman ◽  
Diana L. Franchini ◽  
Marie E. McMillan ◽  
Elena S. Hollender ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Short Course
Sign in / Sign up

Export Citation Format

Share Document